Maria Sepulveda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3869728/publications.pdf

Version: 2024-02-01

59 papers	2,745 citations	236833 25 h-index	189801 50 g-index
60 all docs	60 docs citations	60 times ranked	3326 citing authors

#	Article	IF	Citations
1	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	1.4	241
2	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	4.9	207
3	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	2.8	206
4	Neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e225.	3.1	134
5	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE, 2014, 9, e113936.	1.1	131
6	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor Î±1 Subunit in Patients With Isolated Optic Neuritis. JAMA Neurology, 2015, 72, 187.	4.5	119
7	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	3.1	115
8	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	1.8	112
9	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	1.5	101
10	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology, 2020, 94, e2302-e2310.	1.5	94
11	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	0.9	89
12	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	1.4	87
13	Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Multiple Sclerosis Journal, 2016, 22, 312-319.	1.4	79
14	Acute stroke unit care and early neurological deterioration in ischemic stroke. Journal of Neurology, 2008, 255, 1012-1017.	1.8	77
15	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	1.4	77
16	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Multiple Sclerosis Journal, 2018, 24, 1753-1759.	1.4	71
17	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. PLoS ONE, 2012, 7, e37167.	1.1	68
18	Cognitive functions in multiple sclerosis: impact of gray matter integrity. Multiple Sclerosis Journal, 2014, 20, 424-432.	1.4	47

#	Article	IF	Citations
19	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	1.8	47
20	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	44
21	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	1.5	43
22	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	1.4	36
23	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
24	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	4.5	32
25	Incidence and Impact of COVID-19 in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
26	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. Multiple Sclerosis and Related Disorders, 2020, 38, 101483.	0.9	23
27	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	3.0	23
28	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	0.9	22
29	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	1.4	22
30	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	1.1	21
31	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	1.1	21
32	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	1.4	21
33	Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis. Revue Neurologique, 2022, 178, 121-128.	0.6	21
34	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	1.6	20
35	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle and Nerve, 2017, 56, E162-E167.	1.0	18
36	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	0.9	18

#	Article	IF	Citations
37	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	0.9	17
38	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	4.5	17
39	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports, 2021, 11, 16805.	1.6	17
40	Telemedicine for Monitoring MS Activity and Progression. Current Treatment Options in Neurology, 2015, 17, 47.	0.7	15
41	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	1.8	14
42	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. NeuroImage: Clinical, 2020, 28, 102411.	1.4	11
43	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. Scientific Reports, 2019, 9, 20172.	1.6	10
44	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. Network Neuroscience, 2022, 6, 916-933.	1.4	10
45	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Therapeutic Advances in Neurological Disorders, 2017, 10, 367-372.	1.5	9
46	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	1.4	8
47	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581700.	1.1	8
48	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	1.4	8
49	Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. Patient Preference and Adherence, 2021, Volume 15, 713-719.	0.8	8
50	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	1.1	8
51	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	1.5	7
52	Adult onset Pompe disease associated with multiple sclerosis. Journal of Neurology, 2011, 258, 2286-2287.	1.8	6
53	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. Journal of the Neurological Sciences, 2015, 352, 127-128.	0.3	6
54	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine, 2022, 12, 743.	1.1	6

#	Article	IF	Citations
55	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. Journal of Neurology, 2015, 262, 219-221.	1.8	3
56	Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patientsâ€™ Perspective: An Observational Cross-Sectional Study. Neurology and Therapy, 2022, 11, 1101-1116.	1.4	3
57	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. Biomedicine Hub, 2022, 7, 11-16.	0.4	2
58	Vanishing spinal cord after varicella-zoster virus myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e364.	3.1	1
59	Quantifying the patientÂ´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. PLoS ONE, 2021, 16, e0255317.	1.1	0